#USA #San Diego #pharmaceuticals #Neurocrine #Samir Siddhanti

Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer

Neurocrine Biosciences, Inc. recently announced the significant appointment of Samir Siddhanti as its Chief Business Officer, a move that underscores the company’s commitment to expanding its strategic direction and growth objectives. As part of the executive Management Committee, Siddhanti's new role involves leading the company’s enterprise growth strategy while overseeing critical areas such as business development, corporate strategy, alliance management, and program management.

Siddhanti has been an integral player at Neurocrine since joining the team in 2017. He has progressively taken on leadership roles that have expanded his responsibilities in business development and corporate strategy. Before stepping into his role as Chief Business Officer, Siddhanti was the Vice President of Business Development, where he successfully led numerous strategic transactions that significantly enhanced Neurocrine's commercial portfolio. Noteworthy among these was the recent $2.9 billion acquisition of Soleno Therapeutics.

In addition to his business development leadership, Siddhanti serves as the Program Team Leader for direclidine, a crucial program targeting schizophrenia and bipolar disorder. His extensive experience and leadership are vital in shaping the broader muscarinic portfolio strategy at Neurocrine.

Kyle W. Gano, Ph.D., CEO of Neurocrine Biosciences, praised Siddhanti's contributions, noting his crucial role in formulating the company’s long-term growth strategy, focusing on disciplined portfolio prioritization, and executing transformative business deals. Gano expressed his excitement for Siddhanti's expanded leadership role, confident that his strategic capabilities will help the company grow its pipeline while continuing to seek new opportunities to deliver impactful therapies to patients.

Siddhanti, reflecting on his new position, conveyed gratitude for the trust bestowed upon him by Gano and the leadership team. He emphasized that Neurocrine’s uniqueness stems from its people, its scientific pursuits, and a collective mission to enhance patient lives. His commitment to executing the company's strategic vision and strengthening its pipeline reaffirms Neurocrine's dedication to improving patient outcomes.

Before joining Neurocrine, Siddhanti worked in the biotechnology equity research team at Goldman Sachs. This experience provided him with a strong foundation in the biotechnology sector, further complemented by his academic credentials, holding both a Bachelor of Science and a Master of Science in Management Science and Engineering from Stanford University.

Neurocrine Biosciences stands as a prominent biopharmaceutical entity with a mission to alleviate suffering through the discovery and commercialization of transformative treatments targeting neurological, psychiatric, endocrine, and immunological disorders. With an impressive roster of FDA-approved treatments and a strong pipeline, Neurocrine is committed to tackling unmet medical needs. The company's diverse portfolio currently includes therapies for conditions like tardive dyskinesia, chorea associated with Huntington's disease, and classic congenital adrenal hyperplasia, alongside ongoing developments and collaborations that signify its dynamic approach to pharmaceutical innovation.

As Neurocrine moves forward with Siddhanti at the helm of business operations, expectations run high. The alignment of strategic leadership with scientific innovation poses a promising outlook for the company and its potential to bring forward therapies that can significantly impact the lives of patients suffering from debilitating conditions. Stakeholders and investors will undoubtedly be watching closely as Siddhanti and his team navigate this crucial phase in Neurocrine's journey to redefine patient care through science.

For further information about Neurocrine Biosciences and its initiatives, visit neurocrine.com.